

REMARKS

Applicants have amended the specification to include the priority claim and to move the abstract from the face page of the PCT application to the first page following the claims. Support for the claim amendments appears in, e.g., the original claims and at page 30, lines 12-13 and page 32, lines 10-14 (disclosing that peptides can be degradation products, synthetically synthesized peptides or recombinant peptides). No new matter has been added.

If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Dated: September 1, 2006

Respectfully submitted,

Ivor R. Elriffi, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorneys for Applicant
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

TRA 2193963v.1